Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch... see more

TSX:SVA - Post Discussion

Sernova Corp > In the corner of the diamond
View:
Post by donkeyfeathers on Nov 22, 2022 4:28pm

In the corner of the diamond

Given what appears to be a mass migration over to CEO.CA by the usual suspects (you know who you are, changed na[mm]esakes aside) I will assume that this post will be read by virtually no one, and ask in advance that no one write back on why they need an audience for their announcements over there (you’ve already told on yourselves).  It would seem that Dr. Phil has put himself into a real corner when it comes to testing the patience of shareholders.  First he was unable to suss out the agenda of our research partner in Edmonton (which cost we shareholders much time and money, oh so long ago) then he struck out again in arranging a bought deal that could go absolutely nowhere other than in the back of the large SUV’s owned by Can-of-Crapola and Leeds-all-monies into Mr. Loe’s account.

 

Strike 3 appears to be on the near term horizon.  This is the need to address the cash burn rate relative to what still needs to be done to have what is considered a cure, which cannot be funded, or appears to not be on a funding path, by current institutions who we supposedly have NDA’s with.  This is not to say that new partnerships around funding aren’t being negotiated, but if we look at those two other Swing-and-a-miss episodes, one has to wonder what Evotec sees ahead.  At first I thought that Evotec would simply stabilize the share price by soaking up the share dumps that certain houses have done to line their pockets.  Then I thought, is the risk-on a matter of lack of confidence in company management, or just pure manipulation by non-retail through and through?  Probably both.  

 

For sure, no retail investor wants to have their investment wiped out by algos pushing the price into the $2.80’s only to have the price drop to the $.70’s again.  And the big Pharma partners don’t see any threat from a company that cannot fund the risk-off development process by themselves.  So what of this situation is Dr. Phil ignoring or willfully blinding himself to?  According to all the chatter over on the CEO channel, he must have some secret recipe he’s cooking up that must involve people that are the mirror opposite of the portal vein guy or the bought deal guy.  Now why we should assume that he’s become a much better judge of character, could only really be shown to be true if he himself stepped aside (not completely away) and let someone with real abilities in the area of mergers and acquisitions move in to help relieve some of the restrictions that “the corner” we’re in, imposes.  

 

To my mind, he either sets this up - loads the bases - between now and February 2023, or it will all be taken away from him at the next AGM.  I only believe this given that I don’t need to comment more than once every 3-4 months, because the conversation is going full steam ahead over on CEO.  To my mind this all gets better in 10 months time.  Am I too optimistic?  Maybe.  But I was also the guy who said it was only a matter of time before Phil would wear out his welcome should he continue to believe he could do it all himself long, long before the herd turned on him. 

DF

Comment by steadfast on Nov 22, 2022 8:21pm
Donkey Feathers, as always, you have written an excellent report outlining true SVA facts. It is indeed evident shareholders have lost all confidence of Dr T's ability to continue as CEO, confirming the reality a number of us realized a few years ago. It is time for the Board of Director's to wake up and perform their duties to the Shareholders and to those suffering with diabetes SVA ...more  
Comment by Metalsguy1 on Nov 23, 2022 12:18am
Well put DF. I don't even try to keep up with the chatter on CEO. I am just lying in wait along with others to exit as soon as their is liquidity unless there is a change in management.
Comment by BioTeck on Nov 23, 2022 1:07am
Nice to see people finally waking up and smelling the shiza. 
Comment by MustangSalley on Nov 23, 2022 10:02am
DF, An excellent summary.  Your point is valid about the burn rate . In his only and recent pr in a small rag in London , Ont , Toleikis brags of how how much the company has grown and is hiring from 5 to 29 employees.  The markets response to latest news release and current share price speaks clearly ..... without any capital, it won't matter how good the science is. Pharma ...more  
Comment by BioTeck on Nov 23, 2022 10:59am
Did you see the latest presentation. So much for cohort 2 being fully implanted in 2022, it now just says 2023. Not even Q1. Once PT is mpved to a CSO role, I'll consider buying back some of the stock I have sold in the past. They need to sell this pig. 2 dollars would be a great deal for shareholders and the potential suitor. 
Comment by Mercuryfilling1 on Nov 23, 2022 12:10pm
Any turkey vulture worth his salt will fly ASAP to the potential road kill and spend a lot of time circling before deciding it's safe to go in for the remains. It's impossible to guage the motives of many who have flown over to ceo.ca. but kid yourself not, there are shorters and grifters afoot who want this to drop further. As an example, take the musings of MM on ceo.ca. It was a ...more  
Comment by BioTeck on Nov 23, 2022 12:50pm
Focus on the facts not what forum posters are doing. You're ignoring the fact that in the last communication, cohort 2 was supposed to be completed in 2022. Now it is a vague 2023 completion date.  MM is not Elon Musk with a huge following. Who gives a rats ar$e what he or anyone has to say. Facts are facts and they have been staring everyone in the face. I got called out for bashing ...more  
Comment by Mercuryfilling1 on Nov 23, 2022 6:33pm
"MM is not Elon Musk with a huge following. Who gives a rats ar$e what he or anyone has to say." I'd say the real Moneymouth would care, I certainly care - and you sure seem awfully prickly about it all. Why is that? Huh? Huh? I'm glad you always land on your feet...ha ha.  If you're all that "slimmed down" why do you give a rat's tail about any of ...more  
Comment by BioTeck on Nov 24, 2022 11:40am
It's hard not to land on your feet when the stock you bought cost 10 to 15 cents and averaged that down to near zero by flipping stock for 8 years. I think if anyone here sounds prickly, it's you. I get it, losing your shirt is not fun, especially in the winter. Keep honkin on spills knob for a few more years and maybe he will add you to the option hand outs. Nice to see the usual suspects ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities